These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11422785)

  • 1. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin.
    Quattropani C; Schneider M; Helbling A; Zimmermann A; Krähenbühl S
    Liver; 2001 Jun; 21(3):213-6. PubMed ID: 11422785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical case of the month. Cholestatic hepatitis after administration of piperacillin].
    Dietze MA; Martin P; Schaaf-Lafontaine N
    Rev Med Liege; 2002 Sep; 57(9):571-4. PubMed ID: 12440344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.
    Naber KG; Savov O; Salmen HC
    Int J Antimicrob Agents; 2002 Feb; 19(2):95-103. PubMed ID: 11850161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.
    Karadeniz C; Oğuz A; Canter B; Serdaroğlu A
    Pediatr Hematol Oncol; 2000; 17(7):585-90. PubMed ID: 11033734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
    Dietrich ES; Schubert B; Ebner W; Daschner F
    Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.
    Brismar B; Akerlund JE; Sjöstedt S; Johansson C; Törnqvist A; Bäckstrand B; Bång H; Andåker L; Gustafsson PO; Darle N; Angerås M; Falk A; Tunevall G; Kasholm-Tengve B; Skau T; Nyström PO; Gasslander T; Hagelbäck A; Olsson-Liljequist B; Eklund AE; Nord CE
    Scand J Infect Dis; 1996; 28(5):507-12. PubMed ID: 8953683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of multiple doses of imipenem/cilastatin.
    Drusano GL; Standiford HC; Bustamante CI; Rivera G; Forrest A; Leslie J; Tatem B; Delaportas D; Schimpff SC
    Clin Pharmacol Ther; 1985 May; 37(5):539-43. PubMed ID: 3886256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
    Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S
    Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotoxicity due to imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
    Rivera M; Crespo M; Teruel JL; Marcén R; Ortuño J
    Nephrol Dial Transplant; 1999 Jan; 14(1):258-9. PubMed ID: 10052540
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
    McKinnon PS; Paladino JA; Grayson ML; Gibbons GW; Karchmer AW
    Clin Infect Dis; 1997 Jan; 24(1):57-63. PubMed ID: 8994756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological complication during imipenem/cilastatin therapy in uraemic patients.
    Campise M
    Nephrol Dial Transplant; 1998 Jul; 13(7):1895-6. PubMed ID: 9681765
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cholestasis in imipenem/cilastatin treatment].
    Schreiber C; May B
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():76-7. PubMed ID: 7483723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia.
    Feldman C; White H; O'Grady J; Flitcroft A; Briggs A; Richards G
    Int J Antimicrob Agents; 2001 Mar; 17(3):177-88. PubMed ID: 11282262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
    Cox CE; Holloway WJ; Geckler RW
    Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection.
    Erasmo AA; Crisostomo AC; Yan LN; Hong YS; Lee KU; Lo CM
    Asian J Surg; 2004 Jul; 27(3):227-35. PubMed ID: 15564167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
    Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.